PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: CUSTOMER LANDSCAPE PART 08: MARKET SEGMENTATION BY END-USER • Segmentation by end-user • Comparison by end-user • Hospitals – Market size and forecast 2017-2022 • Physicians' office laboratories – Market size and forecast 2017-2022 • Clinical diagnostic laboratories – Market size and forecast 2017-2022 • Market opportunity by end-user PART 09: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Americas – Market size and forecast 2017-2022 • EMEA – Market size and forecast 2017-2022 • APAC – Market size and forecast 2017-2022 • Market opportunity PART 10: DECISION FRAMEWORK PART 11: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 12: MARKET TRENDS • Increasing demand for POC testing • Emergencw of direct-to-consumer laboratory testing • Online marketing of fecal occult immunological test devices PART 13: VENDOR LANDSCAPE • Overview • Landscape disruption PART 14: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Abbott • Danaher • EIKEN CHEMICAL • Epigenomics • Quidel PART 15: APPENDIX • List of abbreviations Exhibit 01: Parent market Exhibit 02: Market characteristics Exhibit 03: Market segments Exhibit 04: Market definition - Inclusions and exclusions checklist Exhibit 05: Market size 2017 Exhibit 06: Validation techniques employed for market sizing 2017 Exhibit 07: Global fecal occult testing market– Market size and forecast 2017-2022 ($ mn) Exhibit 08: Global fecal occult testing market– Year-over-year growth 2018-2022 (%) Exhibit 09: Five forces analysis 2017 Exhibit 10: Five forces analysis 2022 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2017 Exhibit 17: Customer landscape Exhibit 18: End-user – Market share 2017-2022 (%) Exhibit 19: Comparison by end-user Exhibit 20: Hospitals – Market size and forecast 2017-2022 ($ mn) Exhibit 21: Hospitals – Year-over-year growth 2018-2022 (%) Exhibit 22: Physicians' office laboratories – Market size and forecast 2017-2022 ($ mn) Exhibit 23: Physicians' office laboratories – Year-over-year growth 2018-2022 (%) Exhibit 24: Clinical diagnostic laboratories – Market size and forecast 2017-2022 ($ mn) Exhibit 25: Clinical diagnostic laboratories – Year-over-year growth 2018-2022 (%) Exhibit 26: Market opportunity by end-user Exhibit 27: Global – Market share by geography 2017-2022 (%) Exhibit 28: Regional comparison Exhibit 29: Americas – Market size and forecast 2017-2022 ($ mn) Exhibit 30: Americas – Year-over-year growth 2018-2022 (%) Exhibit 31: Top 3 countries in Americas Exhibit 32: EMEA – Market size and forecast 2017-2022 ($ mn) Exhibit 33: EMEA – Year-over-year growth 2018-2022 (%) Exhibit 34: Top 3 countries in EMEA Exhibit 35: APAC – Market size and forecast 2017-2022 ($ mn) Exhibit 36: APAC – Year-over-year growth 2018-2022 (%) Exhibit 37: Top 3 countries in APAC Exhibit 38: Market opportunity Exhibit 39: Advantages of diagnosis using fecal occult testing over guaiac test, FIT, and stool DNA test Exhibit 40: Barriers in diagnostics market in developing countries Exhibit 41: Some POC FITs available in the market Exhibit 42: Vendor landscape Exhibit 43: Landscape disruption Exhibit 44: Vendors covered Exhibit 45: Vendor classification Exhibit 46: Market positioning of vendors Exhibit 47: Abbott – Overview Exhibit 48: Abbott – Business segments Exhibit 49: Abbott – Organizational developments Exhibit 50: Abbott – Geographic focus Exhibit 51: Abbott – Segment focus Exhibit 52: Abbott – Key offerings Exhibit 53: Danaher – Overview Exhibit 54: Danaher – Business segments Exhibit 55: Danaher – Organizational developments Exhibit 56: Danaher – Geographic focus Exhibit 57: Danaher – Segment focus Exhibit 58: Danaher – Key offerings Exhibit 59: EIKEN CHEMICAL – Overview Exhibit 60: EIKEN CHEMICAL – Business segments Exhibit 61: EIKEN CHEMICAL – Organizational developments Exhibit 62: EIKEN CHEMICAL – Geographic focus Exhibit 63: EIKEN CHEMICAL – Segment focus Exhibit 64: EIKEN CHEMICAL – Key offerings Exhibit 65: Epigenomics – Overview Exhibit 66: Epigenomics – Business segments Exhibit 67: Epigenomics – Organizational developments Exhibit 68: Epigenomics – Geographic focus Exhibit 69: Epigenomics – Segment focus Exhibit 70: Epigenomics – Key offerings Exhibit 71: Quidel – Overview Exhibit 72: Quidel – Business segments Exhibit 73: Quidel – Organizational developments Exhibit 74: Quidel – Geographic focus Exhibit 75: Quidel – Segment focus Exhibit 76: Quidel – Key offerings

Abbott Danaher EIKEN CHEMICAL Epigenomics Quidel